HopeStage
Back to all studies
CompletedNCT02200406

Desvenlafaxine for Depression During Opioid Treatment

About this titleRead the official source — NCT02200406
Medication studyAges 18–65Canada
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
MontrealSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2014
Recruitment status
Completed
Enrollment listed in the registry
18
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT02200406
Official title
Show the full official title

An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Montreal

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Centre hospitalier de l'Université de Montréal (CHUM), a university.

Did this study involve medication?

Yes. The study involved medication, including Desvenlafaxine.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies